CTOs on the Move

Vera Therapeutics

www.veratx.com

 
Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.veratx.com
  • 170 Harbor Way 3rd Floor
    South San Francisco, CA USA 94080
  • Phone: 650.770.0077

Executives

Name Title Contact Details
Scott Rossi
Head of Cybersecurity Profile

Funding

Vera Therapeutics raised $80M on 01/19/2021

Similar Companies

WISDOM TRADITIONS COUNSELING SERVICES

Wisdom Traditions is an Integrative Healthcare Center located in Anchorage Alaska. Specializing in Mind/Body approaches, we offer a variety of services ranging from acupuncture, physical therapy and manual medicine to professional counseling, life c...

Advanced Clinical Services

Advanced Clinical Services is a Deerfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioheart

Founded in 1999, Bioheart, Inc. is committed to the development of effective cell technologies to treat cardiovascular diseases.

Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.